UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549
                                   FORM 10-QSB

(Mark One)
  X      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
----     ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2002

       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
----    ACT OF 1934 FOR THE TRANITION PERIOD FROM  ___________ TO ____________

Commission File Number 2-93277-D



                          MEDIZONE INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)
        Nevada                                           87-0412648
  (State or other jurisdiction             (I.R.S. Employer Identification No.)
of incorporation or organization)

                                 144 Buena Vista
                                  P.O. Box 742
                             Stinson Beach, CA 94970
               (Address of principal executive offices, Zip Code)

                                 (415) 868-0300
              (Registrant's telephone number, including area code)

 Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

At November 8, 2002, there were 157,745,387 shares of the registrant's common
stock issued and outstanding.

Transitional Small Business Disclosure Format
(Check one):
Yes __ No X
         ----


                                       1


<PAGE>


                          MEDIZONE INTERNATIONAL, INC.
                                   FORM 10-QSB
                                      INDEX
                               September 30, 2002

<TABLE>
<CAPTION>
                                                                                                          Page
                                                                                                          Number
Part I -- Financial Information

Item 1 -- Financial Statements

        Consolidated Balance Sheets:
<S>                                                                                                         <C>
         September 30, 2002 (Unaudited) and December 31, 2001................................................3

        Consolidated Statements of Operations (Unaudited):
         For the Three Months and Nine Months Ended September 30, 2002 and 2001..............................4

        Consolidated Statements of Cash Flow (Unaudited)
         For the Nine Months Ended September 30, 2002 and 2001...............................................5

        Notes to Consolidated Financial Statements...........................................................6

Item 2--Management's Discussion and Analysis or Plan of Operation............................................9

Item 3-- Controls and Procedures.............................................................................10

Part II -- Other Information

Item 1-- Legal Proceedings...................................................................................10

Item 2-- Changes in Securities and Use of Proceeds...........................................................11

Item 6-- Exhibits and Reports on Form 8-K....................................................................11
</TABLE>



                                       2


<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                           CONSOLIDATED BALANCE SHEETS
                    September 30, 2002 and December 31, 2001

                                     ASSETS

<TABLE>
<CAPTION>
                                                                             September 30,         December 31,
                                                                                  2002                2001
                                                                            ------------------  ------------------
                                                                               (Unaudited)

CURRENT ASSETS

<S>                                                                         <C>                 <C>
   Cash and cash equivalents                                                $              859  $                -
                                                                            ------------------  ------------------
     Total Current Assets                                                                  859                   -
                                                                            ------------------  ------------------

PROPERTY AND EQUIPMENT (Net)                                                             6,663              10,226
                                                                            ------------------  ------------------

     Total Assets                                                           $            7,522  $           10,226
                                                                            ==================  ==================


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES

   Bank overdraft                                                           $                -  $                8
   Accounts payable                                                                    465,157             397,722
   Advances from shareholders                                                              905                 855
   Accrued expenses                                                                    906,473             743,794
   Notes payable                                                                       303,491             303,491
                                                                            ------------------  ------------------
     Total Current Liabilities                                                       1,676,026           1,445,870
                                                                            ------------------  ------------------

     Total Liabilities                                                               1,676,026           1,445,870
                                                                            ------------------  ------------------

STOCKHOLDERS' EQUITY (DEFICIT)

   Common stock; 250,000,000 shares authorized of $0.001
    par value, 157,745,387 and 155,338,019 shares issued
    and outstanding, respectively                                                      157,745             155,338
   Additional paid-in capital                                                       15,693,550          15,455,220
   Deficit accumulated during the development stage                                (17,519,799)        (17,046,202)
                                                                            ------------------  ------------------

     Total Stockholders' Equity (Deficit)                                           (1,668,504)         (1,435,644)
                                                                            ------------------  ------------------
     Total Liabilities and Stockholders' Equity (Deficit)                   $            7,522  $           10,226
                                                                            ==================  ==================
</TABLE>






              The accompanying notes are an integral part of these
                       consolidated financial statements.


                                       3


<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                                                          From
                                                                                                                      Inception on
                                                            For the                           For the                 January 31,
                                                        Three Months Ended             Nine Months Ended             1986 Through
                                                          September 30,                   September 30,              September 30,
                                               -------------------------------   ---------------------------------
                                                     2002             2001             2002             2001              2002
                                               --------------  ---------------   ---------------  ----------------  ---------------

<S>                                            <C>             <C>               <C>              <C>               <C>
REVENUE                                        $            -  $             -   $             -  $              -  $       133,349
                                               --------------  ---------------   ---------------  ----------------  ---------------

EXPENSES

   Cost of sales                                            -                -                 -                 -          103,790
   Research and development                                 -           42,738            40,602           109,833        2,685,788
   General and administrative                         174,770          125,914           411,690           455,929       13,148,880
   Expense on extension of warrants                         -                -                 -                 -        1,866,857
   Bad debt expense                                         -                -                 -                 -           48,947
   Depreciation and amortization                        1,188            1,356             3,563             4,066           41,333
                                               --------------  ---------------   ---------------  ----------------  ---------------

     Total Expenses                                   175,958          170,008           455,855           569,828       17,895,595
                                               --------------  ---------------   ---------------  ----------------  ---------------

     Loss from Operations                            (175,958)        (170,008)         (455,855)         (569,828)     (17,762,246)
                                               --------------  ---------------   ---------------  ----------------  ---------------

OTHER INCOME (EXPENSES)

   Minority interest in loss                                -                -                 -                 -           26,091
   Other income                                             -                -                 -                 -           19,780
   Gain on sale of subsidiary                               -                -                 -                 -          208,417
   Interest expense                                    (5,914)          (5,972)          (17,742)          (17,192)        (906,579)
                                               --------------  ---------------   ---------------  ----------------  ---------------

     Total Other Income (Expenses)                     (5,914)          (5,972)          (17,742)          (17,192)        (652,291)
                                               --------------  ---------------   ---------------  ----------------  ---------------

LOSS BEFORE EXTRAORDINARY
 ITEMS                                               (181,872)        (175,980)         (473,597)         (587,020)     (18,414,537)
                                               --------------  ---------------   ---------------  ----------------  ---------------

EXTRAORDINARY ITEMS

   Lawsuit settlement                                       -                -                 -                 -          415,000
   Debt forgiveness                                         -                -                 -                 -          479,738
                                               --------------  ---------------   ---------------  ----------------  ---------------

     Total Extraordinary Items                              -                -                 -                 -          894,738
                                               --------------  ---------------   ---------------  ----------------  ---------------

NET LOSS                                       $     (181,872) $      (175,980)  $      (473,597) $       (587,020) $   (17,519,799)
                                               ==============  ===============   ===============  ================  ===============

BASIC INCOME (LOSS) PER SHARE

   Loss from operations                        $        (0.00) $         (0.00)  $         (0.00) $          (0.00)
   Extraordinary items                                   0.00             0.00              0.00              0.00
                                               --------------  ---------------   ---------------  ----------------

     Basic Income (Loss) Per Share             $        (0.00) $         (0.00)  $         (0.00) $          (0.00)
                                               ==============  ===============   ===============  ================

WEIGHTED AVERAGE NUMBER
 OF SHARES OUTSTANDING                            157,505,387      155,338,019       156,680,267       154,956,253
                                               ==============  ===============   ===============  ================
</TABLE>




              The accompanying notes are an integral part of these
                       consolidated financial statements.


                                       4


<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                                      From
                                                                                                   Inception on
                                                                        For the                    January 31,
                                                                    Nine Months Ended              1986 Through
                                                                     September 30,                 September 30,
                                                        --------------------------------------
                                                               2002                2001               2002
                                                        ------------------  ------------------  ------------------

CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                     <C>                 <C>                 <C>
   Net loss                                             $         (473,597) $         (587,020) $      (17,519,799)
   Adjustments to reconcile net loss to net cash
    used by operating activities:
     Depreciation and amortization                                   3,563               4,066              41,333
     Stock issued for services                                      71,000                   -           3,086,916
     Expense for extension of warrants below
      market value                                                       -                   -           1,866,857
     Bad debt expense                                                    -                   -              48,947
     Minority interest in loss                                           -                   -             (26,091)
     Loss on disposal of assets                                          -                   -             693,752
     Gain on settlement of debt                                          -                   -            (188,510)
     Gain on lawsuit settlement                                          -                   -            (415,000)
   Changes in assets and liabilities:
     (Increase) decrease in prepaid expenses
      and deposits                                                       -                   -             (48,947)
     Increase (decrease) in accounts payable                        86,885              32,541             859,687
     Increase (decrease) in accrued expenses                       182,679             270,138           1,329,495
                                                        ------------------  ------------------  ------------------
       Net Cash Used by Operating Activities                      (129,470)           (280,275)        (10,271,360)
                                                        ------------------  ------------------  ------------------

CASH FLOWS FROM INVESTING ACTIVITIES
   Organization costs                                                    -                   -              (8,904)
   Purchase of fixed assets                                              -                   -             (39,090)
                                                        ------------------  ------------------  ------------------
       Net Cash Used by Investing Activities                             -                   -             (47,994)
                                                        ------------------  ------------------  ------------------

CASH FLOWS FROM FINANCING ACTIVITIES
   Bank overdraft                                                       (8)                  -                   -
   Proceeds from lawsuit settlement                                      -                   -             415,000
   Principal payments on notes payable                                   -                   -            (192,774)
   Cash received from notes payable                                      -              23,000           1,129,518
   Advances from shareholders                                        5,337                   -               6,192
   Capital contributions                                                 -                   -             421,847
   Stock issuance costs                                                  -                   -            (105,312)
   Increase in minority interest                                         -                   -              14,470
   Issuance of common stock for cash                               125,000             254,981           8,631,272
                                                        ------------------  ------------------  ------------------
     Net Cash Provided by Financing Activities                     130,329             277,981          10,320,213
                                                        ------------------  ------------------  ------------------
NET INCREASE (DECREASE) IN CASH                                        859              (2,294)                859

CASH AT BEGINNING OF PERIOD                                              -               2,368                   -
                                                        ------------------  ------------------  ------------------
CASH AT END OF PERIOD                                   $              859  $               74  $              859
                                                        ==================  ==================  ==================

SUPPLEMENTAL CASH FLOW INFORMATION
CASH PAID FOR:
   Interest                                             $                -  $                -  $           26,483
   Income taxes                                         $                -  $                -  $                -

NON-CASH FINANCING ACTIVITIES
   Stock issued for services                            $           71,000  $                -  $        3,086,916
   Stock issued for conversion of debt                  $           44,737  $                -  $        4,116,230
   Stock issued for license agreement and patent        $                -  $                -  $          693,752
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.


                                        5

<PAGE>



                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                    September 30, 2002 and December 31, 2001


NOTE 1 -      BASIS OF PRESENTATION

              The financial information included herein is unaudited and has
              been prepared consistent with generally accepted accounting
              principles for interim financial information and with the
              instructions to Form 10-QSB and Item 310(b) of Regulation S-B.
              Accordingly, these financial statements do not include all
              information and footnotes required by generally accepted
              accounting principles for complete financial statements. These
              statements should be read in conjunction with the audited
              financial statements and notes thereto included in the Company's
              annual report on Form 10-KSB for the year ended December 31, 2001.
              In the opinion of management, these financial statements contain
              all adjustments (consisting solely of normal recurring
              adjustments) which are, in the opinion of management, necessary
              for a fair statement of results for the interim period presented.

              The results of operations for the three months and nine months
              ended September 30, 2002 and 2001 are not necessarily indicative
              of the results to be expected for the full year.

NOTE 2 -      LOSS PER SHARE

              Following is a reconciliation of the numerators of the basic and
              diluted loss per share for the three months and nine months ended
              September 30, 2002 and 2001:

<TABLE>
<CAPTION>
                                                                    For the
                                                              Three Months Ended
                                                                  September 30,
                                                    --------------------------------------
                                                            2002                2001
                                                    ------------------  ------------------
              Net loss available to
<S>                                                 <C>                 <C>
               common shareholders                  $       (181,872)   $         (175,980)
                                                    ==================  ==================

              Weighted average shares                      157,505,387         155,338,019
               Effect of dilutive securities                         -                   -
                                                    ------------------  ------------------

                                                           157,505,387         155,338,019
              Basic loss per share (based
               on weighted average
               shares)                              $            (0.00) $            (0.00)
                                                    ==================  ==================

                                                                   For the
                                                              Nine Months Ended
                                                                September 30,
                                                    --------------------------------------
                                                            2002                2001
                                                    ------------------  ------------------

              Net loss available to
               common shareholders                  $         (473,597) $         (587,020)
                                                    ==================  ==================

              Weighted average shares                      156,680,267         154,956,253
               Effect of dilutive securities                         -                   -
                                                    ------------------  ------------------

                                                           156,680,267         154,956,253
              Basic loss per share (based
               on weighted average
               shares)                              $            (0.00) $            (0.00)
                                                    ==================  ==================
</TABLE>


                                       6


<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2002 and December 31, 2001

NOTE 3 -      GOING CONCERN

              The Company's consolidated financial statements are prepared using
              generally accepted accounting principles applicable to a going
              concern, which contemplates the realization of assets and
              liquidation of liabilities in the normal course of business. The
              Company has incurred significant losses from its inception through
              September 30, 2002, which have resulted in an accumulated deficit
              of $17,519,799 at September 30, 2002. The Company does have an
              established source of funds sufficient to cover its operating
              costs, has a working capital deficit of approximately $1,675,000,
              has relied exclusively on debt and equity financing, accordingly,
              there is substantial doubt about its ability to continue as a
              going concern.

              Continuation of the Company as a going concern is dependent upon
              obtaining additional capital, obtaining the requisite approvals
              from the FDA and/or the EU for the marketing of ozone-related
              products and equipment, and ultimately, upon the Company's
              attaining profitable operations. The Company will require a
              substantial amount of additional funds to complete the development
              of its products, to establish manufacturing facilities, to build a
              sales and marketing organization and to fund additional losses,
              which the Company expects to incur over the next several years.

              Because ozone-generation for the purposes of interfacing with
              blood and blood products is regarded as a new drug delivery
              system, the Company is precluded from selling or distributing its
              drug or the Medizone Technology in the United States until after
              FDA approval has been granted. In order to obtain FDA approval,
              the Company will be required to submit a New Drug Application
              ("NDA") for review by the FDA and provide medical and scientific
              evidence sufficient to demonstrate that the drug and the Medizone
              Technology has been successfully used in pre-clinical studies
              followed by three phases of well-controlled clinical studies using
              human volunteer subjects. The FDA will not grant an NDA unless it
              contains sufficient medical evidence and data to permit a body of
              qualified and experienced scientists to conclude that the new drug
              product is safe and effective for its recommended and proposed
              medical uses. Historically, the FDA has held a strong bias against
              treating humans with ozone, due largely to issues of safety.

              In order to initiate the first phase (i.e., Phase I) of human
              clinical trials required as part of an NDA, an applicant must
              submit to the FDA an application for an Investigational New Drug
              Exemption ("IND"), which contains adequate information to satisfy
              the FDA that human clinical trials can be conducted without
              exposing the volunteer human subjects to an unreasonable risk of
              illness or injury. The Company submitted an IND application
              (assigned to the Company by its former president) to the FDA on
              October 6,1985, and requested FDA approval to commence human
              clinical trials using ozone-oxygen to inactivate HIV. The FDA
              deemed the IND application to be incomplete, and required the
              Company to conduct additional animal studies prior to commencing a
              large animal study and human trials. In September 1994, after not
              receiving responses to requests for information from the Company,
              the FDA inactivated the Company's IND. The Company has no present
              plans to commence a large animal study, which would require, as a
              precursor, additional small animal and laboratory work.
              Accordingly, there can be no assurance that the Company's IND
              application will ever be reopened. Until an NDA had been granted
              to the Company, it may not distribute ozone-generating devices,
              except to researchers who agree to follow FDA guidelines, and
              provided the devices are labeled as "Investigational Devices."

              Because ozone has been used to treat humans in Europe for at least
              30 years, the EU is more accepting of human clinical trials of
              ozone therapies being conducted than is the United States.
              Accordingly, management believes that the Company should pursue
              the option of conducting human clinical trials in Europe, using
              stringent protocols that will meet EU standards, with a view to
              utilizing the results of such a trial in an effort to obtain EU
              approval, to market the product in Europe and to reopen the
              Company's FDA file.


                                       7

<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2002 and December 31, 2001

NOTE 3 -     GOING CONCERN (Continued)

              The management of the Company continues to seek additional funding
              which will be utilized to fund additional research and continue
              operations. The Company cautions that, if it is unable to raise
              additional capital, it may find it necessary to substantially
              reduce or cease operations.

              The ability of the Company to continue as a going concern is
              dependent on its ability to successfully accomplish the plan
              described in the preceding paragraphs and eventually attain
              profitable operations. The consolidated financial statements do
              not include any adjustments relating to the recoverability and
              classification of asset carrying amounts or the amount and
              classification of liabilities that might result from the outcome
              of these uncertainties.

NOTE 4 -      STOCK TRANSACTIONS

              During the nine months ended September 30, 2002, the Company
              issued 1,250,000 shares of common stock at $0.10 per share for
              total proceeds of $125,000. The Company also granted the investors
              warrants to purchase 1,250,000 shares of stock at $0.10 per share,
              exercisable over a two-year term. The market price of the common
              stock was $0.10 per share on the date of the issuance of the
              shares and grant of the warrants.

              Also during the nine months ended September 30, 2002, the Company
              issued a total of 677,368 shares of common stock for services
              rendered and repayment of outstanding debt at $0.10 per share for
              a total of $67,737. The Company also issued a total of 480,000
              shares of common stock, pursuant to an S-8 registration, for
              services rendered at $0.10 per share for a total of $48,000.

NOTE 5 -      COMMITMENTS AND CONTINGENCIES

              The Company is subject to certain claims and lawsuits arising in
              the normal course of business. In the opinion of management,
              uninsured losses, if any, resulting from the ultimate resolution
              of these matters will not have a material effect on the Company's
              financial position, results of operations, or cash flows.


                                       8

<PAGE>


Item 2 - Management's Discussion and Analysis or Plan of Operation


Medizone International, Inc., a Nevada corporation ("Medizone") organized in
1986, is a development stage company. To date the principal business of Medizone
has been limited to (1) seeking regulatory approval for its drug, a precise
mixture of ozone and oxygen called MEDIZONE(R), and its process of inactivating
lipid enveloped viruses for the intended purpose of decontaminating blood and
blood products and assisting in the treatment of certain diseases; and (2)
developing or acquiring the related technology and equipment for the medical
application of its products, including its drug production and delivery system.
Due to the lack of sufficient financial resources, all product development has
been placed on hold until a source of funding can be obtained.


Results of Operations


General


From its inception in January 1986, Medizone International has been a
development stage company primarily engaged in research into the medical uses of
ozone. We have never generated, and cannot predict when or if we will generate
revenues or sufficient cash flow to fund continuing operations and planned
research or clinical trials.


Three Months Ended September 30, 2002 compared to the Three Months Ended
September 30, 2001


There were no sales during the quarters ended September 30, 2002 or 2001. We
made no expenditures for research and development during the third quarter of
2002, compared to $42,738 during the third quarter of 2001. Since inception we
have spent a total of $2,685,788 for research and development.


General and administrative expenses in the third quarter of 2002 were $174,770
compared to $125,914 during the third quarter of 2001. These expenses include
primarily legal fees, payroll, insurance costs and other professional fees. The
increase in these expenses reflects the ongoing legal fees and other costs
incurred, additional salaries and the limited business conducted by the company
during the quarter as efforts to obtain financing continued.


Interest expense accrued during the three months ended September 30, 2002 was
$5,914 compared to $5,972 in the three months ended September 30, 2001.


Nine Months Ended September 30, 2002 compared to the Nine Months Ended September
30, 2001:


There were no sales during the nine months ended September 30, 2002 or 2001. We
made expenditures for research and development of $40,602 during the nine months
ended September 30, 2002, compared to research and development expenditures of
$109,833 in the nine months ended September 30, 2001.


General and administrative expenses in the first nine months of 2002 were
$411,690 compared to $455,929 during the first nine months of 2001. The
reduction in these expenses reflects the reduction in employees and the limited
business conducted by the company during the year as efforts to obtain financing
continued.


Interest expense accrued during the nine months ended September 30, 2002 was
$17,742, compared to $17,192 in the nine months ended September 30, 2001.


Liquidity and Capital Resources


At September 30, 2002, we had a working capital deficiency of $1,675,167 and
stockholders' deficiency of $1,668,504. At December 31, 2001, we had a working
capital deficiency of $1,445,870 and stockholders' deficiency of $1,435,644.


Net cash used in operating activities was $129,470 for the nine months ended
September 30, 2002. Cash of $125,000 was provided during the first nine months
of 2002 from the sale and issuance of common stock. During the nine months ended
September 30, 2001, net cash used in operating activities was $280,275. Cash of
$254,981 was provided in the first nine months of 2001 by the sale of common
stock through the exercise of outstanding stock purchase warrants.


The company continues to require additional funding to enable it to operate and
to fund research necessary to make the appropriate regulatory application and
continue operations. We expect that these funds will be provided by the sale of
our securities. We recognize that, if we are unable to raise additional capital,
we may find it necessary to substantially reduce, or cease operations.


                                       9

<PAGE>


Forward-Looking Statements and Risks Affecting the Company

The statements contained in this Report on Form 10-QSB that are not purely
historical are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and Section 21E of the Securities
Exchange Act. These statements regard our expectations, hopes, beliefs,
anticipations, commitments, intentions and strategies regarding the future. They
may be identified by the use of the words or phrases "believes," "expects,"
"anticipates," "should," "plans," "estimates," and "potential," among others.
Forward-looking statements include, but are not limited to, statements contained
in Management's Discussion and Analysis of or Plan of Operation regarding our
financial performance, revenue and expense levels in the future and the
sufficiency of existing assets to fund future operations and capital spending
needs. Actual results could differ materially from the anticipated results or
other expectations expressed in such forward-looking statements for the reasons
detailed in our Annual Report on Form 10-KSB for the year ended December 31,
2001 under the headings "Description of Business" and "Risk Factors." The fact
that some of the risk factors may be the same or similar to past reports filed
with the Securities and Exchange Commission means only that the risks are
present in multiple periods. We believe that many of the risks detailed here and
in our SEC filings are part of doing business in the industry in which we
operate and compete and will likely be present in all periods reported. The fact
that certain risks are endemic to the industry does not lessen their
significance. The forward-looking statements contained in this report are made
as of the date of this Report and we assume no obligation to update them or to
update the reasons why actual results could differ from those projected in such
forward-looking statements. Among others, risks and uncertainties that may
affect our the business, financial condition, performance, development, and
results of operations include:

        o   Rigorous government scrutiny and regulation of our products and
            planned products;

        o   Potential effects of adverse publicity regarding ozone and related
            technologies or industries;

        o   Failure to sustain or manage growth including the failure to
            continue to develop new products; and

        o   The ability to obtain needed financing.


Item 3.  Controls and Procedures

Under the supervision and with the participation of our management, we have
evaluated the effectiveness of the design and operation of our disclosure
controls and procedures within 90 days of the filing date of this quarterly
report, and, based on that evaluation, Mr. Marshall and Mr. Hanni, our CEO and
CFO, respectively, have concluded that these controls and procedures are
effective. There were no significant changes in our internal controls or in
other factors that could significantly affect these controls subsequent to the
date of their evaluation.

Disclosure controls and procedures are our controls and other procedures that
are designed to ensure that information required to be disclosed by us in the
reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Securities and
Exchange Commission's rules and forms. Disclosure controls and procedures are
designed to ensure that information required to be disclosed by us in the
reports that we file under the Exchange Act is accumulated and communicated to
our management, as appropriate to allow timely decisions regarding required
disclosure.


                           Part II--Other Information


Item 1.  Legal Proceedings


Medizone International, Inc. vs. Nathaniel Bottomly, Ross Bottomly, Jeff Pace et
al., Civil No. CO2 1659CRB (United States District Court,  Northern  District of
California).  On October 10,  2002,  the company  filed a motion to dismiss this
matter without prejudice, permitting the company to refile the action in federal
court in Utah. The court subsequently granted the motion.


                                       10

<PAGE>


Item 2.  Changes in Securities and Use of Proceeds

During the nine months ended September 30, 2002, the company sold 1,250,000
shares of common stock to accredited investors at $0.10 per share, or gross
proceeds of $125,000. We also granted these investors warrants to purchase
1,250,000 shares of stock at $0.09 and $0.10 per share, exercisable over a
two-year term.


The purchasers of the common stock and warrants were accredited investors as
that term is defined under the Securities Act of 1933 and the securities were
sold in private transactions pursuant to an exemption from the registration
requirements under the Securities Act, specifically the exemption under Section
4(2) of the Securities Act applicable to offers and sales made to accredited
investors only and offers and sales that are not made in a public offering.


Also during the nine months ended September 30, 2002, the company issued 677,368
shares of common stock for services rendered and repayment of outstanding debt
at a per share price of $0.10 for a total of $67,737. The company also issued a
total of 480,000 shares of common stock pursuant to a registration statement
filed on Form S-8, for services rendered. These shares had an agreed value on
the date issued of $0.10 per share or a total of $48,000.


Item 6.  Exhibits and Reports on Form 8-K

(a)       Exhibits Required by Item 601 of Regulation S-B

         Number            Description


         2                 Agreement and Plan of Reorganization dated March 12,
                           1986 (2)


         3.1               Articles of Incorporation of Company (2)


         3.2               Bylaws (2)


         3.3               Articles of Amendment to Company's Articles of
                           Incorporation (3)


         10.1              Patent Agreement, dated February 26, 1987. (3)


         10.2              Assignment of  Distributor  Agreement by Terrence O.
                           McGrath to Medizone  Delaware,  dated February 4,
                           1986, and Distributor Agreement between Terrence O.
                           McGrath and Dr. J. Hansler GmbH, dated September 25,
                           1985 (3)


         10.3              Letter  confirmation and Protocol,  dated June 2,
                           1986, with regard to research to be conducted by the
                           State University of New York at Syracuse (2)


         10.4              Consulting Agreement between P.J. Watrous & Co., Inc.
                           and Medizone (2)


         10.5              Consulting Agreement between Jeffrey Freed, MD, PC
                           and Medizone (2)


         10.6              Consulting Agreement between Joseph Latino and
                           Medizone (2)


         10.7              Consulting Agreement between Susan Golden, RN and
                           Medizone (2)


         10.8              Stock Option of Joseph Latino (2)


         10.9              Stock Option of Jeffrey Freed (2)


         10.10             Stock Option of Susan Golden (2)


         10.11             Stock Option of Hubert Weinberg (2)


         10.12             Agreement dated June 16, 1987, between Company and
                           Oliver Grace (5)


         10.13             Agreement dated June 26, 1987, between Company and
                           John Grace (5)


         10.14             Agreement dated June 26, 1987, between Company and
                           Oliver Grace (5)


                                       11

<PAGE>

         10.15             Agreement  dated June 30, 1987,  by and among Company
                           and John C.  Black,  Dr.  Gerard V.  Sunnen and Dr.
                           Priyakant S. Doshi (5)


         10.16             License Agreement with MCL Medizone Canada Ltd. dated
                           November 18, 1987 (5)


         10.17             Agreement  dated October 1988 by and among
                           Immunologics,  Limited  Partnership,  John M. Kells,
                           Y. C. Zee, David C. Bolton and Medizone
                           International, Inc. (6)


         10.18             Form of Stock Purchase Agreement between Company and
                           individuals who purchased shares from Company (7)


         10.19             Letter agreement between Company and Rebus Oil Co.,
                           Ltd. dated July 28, 1992 (8)


         10.20             Letter of understanding between Company and the RMB
                           Group of Boston dated August 10, 1992 (8)


         10.21             Agreement between Company and Rebus Oil Company,
                           Ltd., dated as of October 20, 1992 (9)


         10.22             Letter  agreement among Messrs.  McGrath,  Watrous,
                           Melera,  Chou,  Kells, Handel and Pealer, dated as of
                           November 10, 1992 (9)


         10.23             Loan agreement with Messrs. McGrath and Watrous dated
                           as of November 16, 1992 (9)


         10.24             Settlement agreement with former consultant dated
                           February 12, 1993 (9)


         10.25             Consulting Agreement with Joseph S. Latino dated as
                           of January 1, 1993 (9)


         10.26             Consulting Agreement with Arthur P. Bergeron dated as
                           of January 1, 1993 (9)


         10.27             Employment Agreement with Katherine M. Kalinowski
                           dated as of January 1, 1993 (9)


         10.28             Consulting Agreement with Roger Shelley dated as of
                           January 1, 1993 (9)


         10.29             Consulting Agreement with Jeannette Arsenault dated
                           as of January 1, 1993 (9)


         10.30             Loan Agreements between Company and John Kells,
                           George Handel and John Pealer,  executed as of June
                           11, 1993 (and promissory notes) (9)


         10.31             Promissory  Note to Joseph S. Latino dated as of
                           October 26, 1993 and  Acceptance  Form dated as of
                           November 26, 1993 (9)


         10.32             Letter Agreement dated March 23, 1993 between Company
                           and the Italian Scientific Society (10)


         10.33             Contract between Company and Capmed USA (10)


         10.34             Agreement made as of May 18, 1994, among Medizone
                           International,  Inc., Medizone Canada Ltd., John M.
                           Kells, George Handel, John Pealer, Joseph S. Latino,
                           Terrence O. McGrath and Philip J. Watrous (11)


         10.35             Agreement made as of January 1, 1995, between
                           Medizone International, Inc. and Joseph S.Latino (11)


         10.36             Agreement made as of January 1, 1995 between Medizone
                           International, Inc. and Arthur P. Bergeron (11)


         10.37             Agreement made as of January 1, 1995 between Medizone
                           International, Inc. and Giacomo C. DiGiorgio, MD (11)


         10.38             Lease  Agreement  between  Medizone  International,
                           Inc. and Benabi Realty,  made on September 27, 1991,
                           as extended, January 17, 1995 (11)


                                       12

<PAGE>


         10.39             Agreement  for Sale and Purchase of Shares in
                           Medizone New Zealand  Limited  between  Richard G.
                           Solomon and Medizone International, Inc., dated June
                           22, 1995 (12)


         10.40             Shareholders'  Agreement  relating to Medizone  New
                           Zealand Limited  between and among Solwin Investments
                           Limited, Medizone International, Inc. and Medizone
                           New Zealand Limited, dated June 22, 1995 (12)


         10.41             Licensing Agreement between Medizone International,
                           Inc. and MNZ, dated June 22, 1995 (12)


         10.42             Managing Agent Agreement between Medizone
                           International, Inc. and Medizone New Zealand Limited,
                           dated June 22, 1995 (12)


         10.43             Lease Agreement between Medizone International, Inc.
                           and Linmar L.P., dated January 17, 1996 (13)


         10.44             Agreement between Medizone International, Inc. and
                           Multiossigen S.r.l., dated as of September 13,
                           1996 (14)


         10.45             Agreement between Medizone International, Inc. and
                           JRH Biosciences, Inc., dated April 17, 1997 (15)

         10.46             Lease Agreement between Medizone International Inc.
                           and Eagle Overlook, L.C., made on September 23,
                           1997 (16)

         16                Funding commitment letter from Groundell Trust. (17)


         99.1              Certification under Section 906 of the Sarbanes-Oxley
                           Act.





(1)      Incorporated by reference to Medizone's annual report on form 10-K for
         the year ended December 31, 1998.


(2)      Incorporated by reference to Medizone's  registration  statement on
         Form S-18 (Registration No. 2-93277-D),  effective May 14, 1985.


(3)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1986.


(4)      Incorporated by reference to Medizone's current report on Form 8-K,
         filed March 13, 1987.


(5)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1987.


(6)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1988.


(7)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1989.


(8)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1990.


(9)      Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1992.


(10)     Incorporated by reference to Medizone's current annual report on Form
         8-K dated September 8, 1993.


(11)     Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1994.


(12)     Incorporated by reference to Medizone's current annual report on Form
         8-K, dated June 22, 1995.


(13)     Incorporated by reference to Medizone's annual report on Form 10-K for
         the period ended December 31, 1995.


(14)     Incorporated by reference to Medizone's current report on Form 8-K,
         dated October 17, 1996.


(15)     Incorporated by reference to Medizone's current report on Form 8-K,
         dated May 5, 1997.


                                       13

<PAGE>


(16)     Incorporated by reference to Medizone's current report on Form 8-K
         dated September 24, 1997.

(17)     Incorporated by reference to Medizone's annual report on Form 10-KSB
         for the year ended December 31, 2001.


(b)      Reports on Form 8-K

         None.


                                     14

<PAGE>


                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                 MEDIZONE INTERNATIONAL, INC.
                                 (Registrant)

                                 /s/ Edwin G. Marshall
                                 ---------------------------
                                 Edwin G. Marshall, Chairman and Chief Executive
                                 Officer (Principal Executive Officer)


                                 /s/ Steve M. Hanni
                                 -----------------------------------
                                 Steve M. Hanni, Chief Financial Officer
                                 (Principal Accounting Officer)



November 13, 2002



                                       15

<PAGE>



                                 CERTIFICATIONS


I, Edwin G. Marshall, Chairman and CEO, certify that:


         1.       I have reviewed this quarterly report on Form 10-QSB of
                  Medizone International, Inc.;


         2.       Based on my knowledge, this quarterly report does not contain
                  any untrue statement of a material fact or omit to state a
                  material fact necessary to make the statements made, in light
                  of the circumstances under which such statements were made,
                  not misleading with respect to the period covered by this
                  quarterly report;


         3.       Based on my knowledge, the financial statements, and other
                  financial information included in this quarterly report,
                  fairly present in all material respects the financial
                  condition, results of operations and cash flows of the
                  registrant as of, and for, the periods presented in this
                  quarterly report;


         4.       The registrant's other certifying officers and I are
                  responsible for establishing and maintaining disclosure
                  controls and procedures (as defined in Exchange Act Rules
                  13a-14 and 15d-14) for the registrant and have:


                  a)       designed such disclosure controls and procedures to
                           ensure that material information relating to the
                           registrant, including its consolidated subsidiaries,
                           is made known to us by others within those entities,
                           particularly during the period in which this
                           quarterly report is being prepared;


                  b)       evaluated the effectiveness of the registrant's
                           disclosure controls and procedures as of a date
                           within 90 days prior to the filing date of this
                           quarterly report (the "Evaluation Date"); and


                  c)       presented in this quarterly report our conclusions
                           about the effectiveness of the disclosure controls
                           and procedures based on our evaluation as of the
                           Evaluation Date;


         5.       The registrant's other certifying officers and I have
                  disclosed, based on our most recent evaluation, to the
                  registrant's auditors and the audit committee of registrant's
                  board of directors (or persons performing the equivalent
                  functions):


                  a)       all significant deficiencies in the design or
                           operation of internal controls which could adversely
                           affect the registrant's ability to record, process,
                           summarize and report financial data and have
                           identified for the registrant's auditors any material
                           weaknesses in internal controls; and


                  b)       any fraud, whether or not material, that involves
                           management or other employees who have a significant
                           role in the registrant's internal controls; and


         6.       The registrant's other certifying officers and I have
                  indicated in this quarterly report whether or not there were
                  significant changes in internal controls or in other factors
                  that could significantly affect internal controls subsequent
                  to the date of our most recent evaluation, including any
                  corrective actions with regard to significant deficiencies and
                  material weaknesses.


         Date: November 13, 2002


         /s/ Edwin G. Marshall
         --------------------------------------------
         Edwin G. Marshall, Chairman and CEO



                                       16


<PAGE>



I, Steve M. Hanni, CFO, certify that:


         1.       I have reviewed this quarterly report on Form 10-QSB of
                  Medizone International, Inc.;


         2.       Based on my knowledge, this quarterly report does not contain
                  any untrue statement of a material fact or omit to state a
                  material fact necessary to make the statements made, in light
                  of the circumstances under which such statements were made,
                  not misleading with respect to the period covered by this
                  quarterly report;


         3.       Based on my knowledge, the financial statements, and other
                  financial information included in this quarterly report,
                  fairly present in all material respects the financial
                  condition, results of operations and cash flows of the
                  registrant as of, and for, the periods presented in this
                  quarterly report;


         4.       The registrant's other certifying officers and I are
                  responsible for establishing and maintaining disclosure
                  controls and procedures (as defined in Exchange Act Rules
                  13a-14 and 15d-14) for the registrant and have:


                  a)       designed such disclosure controls and procedures to
                           ensure that material information relating to the
                           registrant, including its consolidated subsidiaries,
                           is made known to us by others within those entities,
                           particularly during the period in which this
                           quarterly report is being prepared;


                  b)       evaluated the effectiveness of the registrant's
                           disclosure controls and procedures as of a date
                           within 90 days prior to the filing date of this
                           quarterly report (the "Evaluation Date"); and


                  c)       presented in this quarterly report our conclusions
                           about the effectiveness of the disclosure controls
                           and procedures based on our evaluation as of the
                           Evaluation Date;


         5.       The registrant's other certifying officers and I have
                  disclosed, based on our most recent evaluation, to the
                  registrant's auditors and the audit committee of registrant's
                  board of directors (or persons performing the equivalent
                  functions):


                  a)       all significant deficiencies in the design or
                           operation of internal controls which could adversely
                           affect the registrant's ability to record, process,
                           summarize and report financial data and have
                           identified for the registrant's auditors any material
                           weaknesses in internal controls; and


                  b)       any fraud, whether or not material, that involves
                           management or other employees who have a significant
                           role in the registrant's internal controls; and


         6.       The registrant's other certifying officers and I have
                  indicated in this quarterly report whether or not there were
                  significant changes in internal controls or in other factors
                  that could significantly affect internal controls subsequent
                  to the date of our most recent evaluation, including any
                  corrective actions with regard to significant deficiencies and
                  material weaknesses.


         Date: November 13, 2002


         /s/ Steve M. Hanni
         --------------------------------------------
         Steve M. Hanni, Chief Financial Officer


                                       17


<PAGE>


EXHIBIT 99.1


                   CERTIFICATION OF PERIODIC FINANCIAL REPORTS

         The undersigned hereby certify that to the best of their knowledge the
Quarterly Report on Form 10-QSB of Medizone International, Inc. for the
quarterly period ended September 30, 2002, as filed November 13, 2002 with the
Securities and Exchange Commission, fully complies with the requirements of
Section 13(a) of The Securities Exchange Act of 1934 (15 U.S.C. 78m) and that to
the best of their knowledge the information contained in the quarterly report
fairly presents, in all material respects, the financial condition and results
of operations of Medizone International, Inc.



Date: November 13, 2002         /s/ Edwin G. Marshall
                                ----------------------------------------
                                Edwin G. Marshall
                                Chairman and Chief Executive Officer
                                Principal Executive Officer)


Date: November 13, 2002         /s/ Steve M. Hanni
                                ----------------------------------------
                                Steve M. Hanni
                                Chief Financial Officer
                                (Principal Financial and Accounting Officer)







                                       18